Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Despite viral suppression, antiretroviral therapy (ART) does not restore CD4+ T-cell counts
in some subjects. The purpose of this study is to assess whether adding maraviroc (MVC) to a
suppressive ART will result in a significant CD4+ T-cell count increase over 24 weeks in
subjects with suboptimal CD4+ T-cell recovery despite sustained virologic suppression.
Phase:
N/A
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)